BRMS1L: A Potential Drug Target for Breast Cancer (G84312)

Target Name: BRMS1L

NCBI ID: G84312

BRMS1L

BRMS1L: A Potential Drug Target for Breast Cancer

Breast cancer is a common malignant tumor that seriously threatens women's health. The pathogenesis of breast cancer is usually divided into two stages: the primary stage and the metastatic stage. In the primary stage, tumors gradually grow in the breast tissue, forming nodules or masses. In the metastasis stage, the tumor enters other tissues and organs through the blood or lymphatic system and forms metastases. Metastasis is one of the leading causes of death in breast cancer patients.

Although the current treatment methods for breast cancer have become more and more diverse, there are still many patients who cannot be cured. Metastasis is one of the main reasons why breast cancer patients cannot be cured.

In recent years, researchers have discovered new treatments and drugs that they hope will treat breast cancer and improve patient survival. One of them is BRMS1L, a breast cancer gene mutant that is considered a potential drug target.

BRMS1L is a breast cancer gene mutant located on human chromosome 1p36.1. Research has found that BRMS1L gene mutants play an important role in breast cancer tissues and cells. It is closely related to breast cancer progression and treatment response.

The protein expressed by the BRMS1L gene mutant is a protein called BRMS1L. The BRMS1L protein is caused by genetic mutations within breast cancer cells. These genetic mutations can lead to changes in the structure or function of the BRMS1L protein, which can lead to the growth and spread of breast cancer cells.

The role of the BRMS1L protein in breast cancer treatment is being intensively studied. Some studies have suggested that the BRMS1L protein could serve as a target for the treatment of breast cancer. By inhibiting the action of the BRMS1L protein, the growth and spread of breast cancer cells can be slowed, thereby improving the effectiveness of treatment.

In addition, some studies have shown that the BRMS1L protein can predict the survival rate of breast cancer patients. Studies have found that the expression level of BRMS1L protein is negatively correlated with the survival rate of breast cancer patients. This means that breast cancer patients expressing higher levels of BRMS1L have lower survival rates.

Therefore, the BRMS1L protein is being studied intensively as a new therapeutic target.

Protein Name: BRMS1 Like Transcriptional Repressor

Functions: Involved in the histone deacetylase (HDAC1)-dependent transcriptional repression activity. When overexpressed in lung cancer cell line that lacks p53/TP53 expression, inhibits cell growth

The "BRMS1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRMS1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets